CDMO

€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.

Passed a two-week unannounced FDA GMP inspection covering drug substance and drug product manufacturing, reinforcing U.S. commercial supply reliability.

Shows preservative solutions for pet care, launches biodegradable Cosmelin esters as a silicone alternative, presents Scopeblue lower‑carbon preservatives and an Oct 16 LCA talk.

Aligns businesses by role, assigns roles to six German sites, and shifts investment to Asia/Americas; launches growth projects in Canada and Slovakia, funded by cost cuts.

First subcutaneous immune‑checkpoint inhibitor in Japan; can be given in as little as one minute and showed comparable exposure and response to IV pembrolizumab in a phase‑3 trial.

EUR 80m upgrade adds downstream fermentation capacity for complex pharma intermediates, targets completion early 2028 and about 50 new jobs; site runs on 100% green electricity.

Framework to boost EU production capacity, guide R&D and investments, and reduce dependence on Russian isotopes and HALEU.

Joint research will advance manufacturing, automation and quality-control for cell and gene therapies to expand Japan's manufacturing infrastructure and patient access.

New plant adds clinical-scale lipid nanoparticle drug product capacity with federal support; production is planned to start at the end of 2029.

End-to-end CDMO support for NTX-083 completed — manufacturing process established and IND CMC documentation prepared ahead of planned US clinical trials in 2026.